Theravac (docusate) / Institut Pasteur - LARVOL DELTA

Reactive Oxygen Species-Sensitive Biodegradable Mesoporous Silica Nanoparticles Harboring TheraVac Elicit Tumor-Specific Immunity for Colon Tumor Treatment. (PubMed, ACS Nano) - "Thus, MSN@TheraVac provides a timely release of TheraVac for the curative treatment of colon tumors and holds potential for translation into a clinical therapy for patients with immunologically "cold" colorectal cancers. This ROS-responsive MSN platform may also be tailored for the selective delivery of other cancer vaccines for effective immunotherapy."

IO biomarker • Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD80 • CD86 • HMGN1 • IL12A • IL1B • ITGAE • TNFA

Development of a novel modified vaccine (TheraVac) for curative treatment of mouse solid tumors. (PubMed, Cytokine) - "The resultant tumor-free mice were resistant to subsequent re-challenge with the same tumors, indicating the generation of long-term tumor specific protective immunity. Since the immune-activating arm also induces full maturation of human DCs, and anti-PDL-1 or anti-CTLA4 have been FDA-approved, this combinational immunotherapy has the potential to be an effective clinical therapy for patients with solid tumors."

Journal • Preclinical • Colorectal Cancer • Genito-urinary Cancer • Immune Modulation • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • HMGN1

A Therapeutic Vaccine in Combination with Cyclic GMP-AMP Cures More Differentiated Melanomas in Mice. (PubMed, J Immunol) - "We have identified a combinational immunotherapy termed TheraVac vaccine (TheraVac) that can cure multiple large established mouse tumors, but it failed to cure melanoma in mice...The resultant tumor-free mice were selectively resistant to subsequent challenge with the same tumors, indicating long-term tumor-specific protective immunity. Overall, our findings have important implications for clinical trials with a combination of these immunotherapeutics to cure melanin-producing human melanomas, without the need for exogenous tumor Ags and no clear toxic effects in mice."

Combination therapy • Journal • Preclinical • Immune Modulation • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • HMGN1 • TLR4 • TLR7 • TNFA

[VIRTUAL] Therapeutic Vaccine (TheraVac) in combination with cGAMP cures more differentiated melanomas in mice (IMMUNOLOGY 2021) - "The resultant tumor-free mice were selectively resistant to subsequent challenge with the same tumors, indicating long-term tumor specific protective immunity. Overall, our findings have important implications for clinical trials with a combination of immunotherapeutics to cure melanin producing human melanomas, without the need for exogenous tumor antigens and no obvious toxic effects in mice."

Combination therapy • Preclinical • Immune Modulation • Immunology • Inflammation • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • TLR4 • TNFA

[VIRTUAL] Therapeutic Vaccine (TheraVac) in combination with cGAMP cures more differentiated melanomas in mice (IMMUNOLOGY 2021) - P1 | "The resultant tumor-free mice were selectively resistant to subsequent challenge with the same tumors, indicating long-term tumor specific protective immunity. Overall, our findings have important implications for clinical trials with a combination of immunotherapeutics to cure melanin producing human melanomas, without the need for exogenous tumor antigens and no obvious toxic effects in mice."

Combination therapy • Preclinical • Immune Modulation • Inflammation • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • TLR4 • TNFA

Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. (PubMed, Sci Rep) - "Intratumoral delivery of HMGN1 with low dose of Cytoxan cured mice bearing small (∅ ≈ 0.5 cm), but not large (∅ ≈ 1.0 cm) CT26 tumors. Importantly, this immunotherapeutic regimen was also curative for large established mouse Renca and EG7 tumors. Thus, we have developed a curative therapeutic vaccination regimen dubbed 'TheraVac' consisting of HMGN1 and R848 plus a checkpoint inhibitor, that can, without using exogenous tumor-associated antigen(s), eliminate various large tumors and induce tumor-specific immunity."

Journal